What is Egalet?
Egalet Corporation is a specialty pharmaceutical entity dedicated to the development, manufacturing, and commercialization of innovative treatments for pain and related conditions. The company distinguishes itself through its proprietary Guardian Technology, which focuses on creating abuse-deterrent, extended-release formulations. Its current product suite includes SPRIX Nasal Spray, OXAYDO, and ARYMO ER, each designed to provide effective analgesia while mitigating the risks associated with opioid misuse.
Beyond its commercialized products, Egalet maintains a robust pipeline, including Phase III clinical candidates such as Egalet-002. By leveraging strategic partnerships with industry players like Acura Pharmaceuticals and Septodont, the company has established a scalable commercial footprint. Its operational model integrates advanced drug delivery science with a clear regulatory strategy, positioning it as a significant contributor to the evolving landscape of pain management and patient safety.
How much funding has Egalet raised?
Egalet has raised a total of $207.5M across 6 funding rounds:
Share Placement
$13.3M
Series B
$33.6M
Unspecified
$20M
Stock Offering
$58.4M
Debt
$40M
Unspecified
$42.2M
Share Placement (2001): $13.3M with participation from Dask Kapitalanlaeg, Danske Bank, QueQuoin Holdings, and Bio Fund
Series B (2012): $33.6M led by Bio Fund, Vaekstfonden Life Science Ventures, Danske Bank, Index Ventures, Sunstone Capital, Dansk Kapitalanlaeg, Omega Funds, QueQuoin Holdings, Atlas Ventures, and CLS Capital
Unspecified (2013): $20M supported by Index Ventures
Stock Issuance/Offering (2014): $58.4M featuring Undisclosed
Debt (2016): $40M backed by Morgan Stanley & Co.
Unspecified (2019): $42.2M with participation from Undisclosed
Key Investors in Egalet
Index Ventures
Index Ventures is a venture firm investing in the next generation of entrepreneurs from seed to IPO, partnering with founders who challenge the status quo to build enduring companies.
Sunstone Capital
Sunstone Life Science Ventures is an independent European venture capital firm focused on enabling and empowering life science therapeutics innovations to improve patient outcomes.
Atlas Ventures
Atlas Venture is a pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines.
What's next for Egalet?
Looking ahead, Egalet is poised to leverage its recent capital influx to accelerate the clinical progression of its late-stage pipeline candidates. The strategic focus remains on the successful execution of Phase III trials and the potential market entry of its next-generation abuse-deterrent stimulants and hydrocodone-based products. As the company matures, the emphasis will likely shift toward optimizing commercial distribution channels and expanding its therapeutic reach through continued collaborative licensing agreements.
The firm's ability to maintain a balance between R&D innovation and commercial viability will be the primary driver of its long-term value creation. With a solid foundation of institutional support and a clear regulatory roadmap, Egalet is well-positioned to navigate the challenges of the pharmaceutical industry while addressing the urgent need for safer, more effective pain management solutions.
